• Je něco špatně v tomto záznamu ?

Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma

P. Bucher, T. Erdmann, P. Grondona, W. Xu, A. Schmitt, C. Schürch, M. Zapukhlyak, C. Schönfeld, E. Serfling, D. Kramer, M. Grau, P. Klener, C. Lengerke, K. Schulze-Osthoff, G. Lenz, S. Hailfinger,

. 2020 ; 135 (2) : 121-132. [pub] 20200109

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023237

Diffuse large B-cell lymphoma (DLBCL) represents the most common adult lymphoma and can be divided into 2 major molecular subtypes: the germinal center B-cell-like and the aggressive activated B-cell-like (ABC) DLBCL. Previous studies suggested that chronic B-cell receptor signaling and increased NF-κB activation contribute to ABC DLBCL survival. Here we show that the activity of the transcription factor NFAT is chronically elevated in both DLBCL subtypes. Surprisingly, NFAT activation is independent of B-cell receptor signaling, but mediated by an increased calcium flux and calcineurin-mediated dephosphorylation of NFAT. Intriguingly, although NFAT is activated in both DLBCL subtypes, long-term calcineurin inhibition with cyclosporin A or FK506, both clinically approved drugs, triggers potent cytotoxicity specifically in ABC DLBCL cells. The antitumor effects of calcineurin inhibitors are associated with the reduced expression of c-Jun, interleukin-6, and interleukin-10, which were identified as NFAT target genes that are particularly important for the survival of ABC DLBCL. Furthermore, calcineurin blockade synergized with BCL-2 and MCL-1 inhibitors in killing ABC DLBCL cells. Collectively, these findings identify constitutive NFAT signaling as a crucial functional driver of ABC DLBCL and highlight calcineurin inhibition as a novel strategy for the treatment of this aggressive lymphoma subtype.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023237
003      
CZ-PrNML
005      
20201214125544.0
007      
ta
008      
201125s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood.2019001866 $2 doi
035    __
$a (PubMed)31794606
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bucher, Philip $u Interfaculty Institute for Biochemistry, Eberhard Karls University, Tübingen, Germany.
245    10
$a Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma / $c P. Bucher, T. Erdmann, P. Grondona, W. Xu, A. Schmitt, C. Schürch, M. Zapukhlyak, C. Schönfeld, E. Serfling, D. Kramer, M. Grau, P. Klener, C. Lengerke, K. Schulze-Osthoff, G. Lenz, S. Hailfinger,
520    9_
$a Diffuse large B-cell lymphoma (DLBCL) represents the most common adult lymphoma and can be divided into 2 major molecular subtypes: the germinal center B-cell-like and the aggressive activated B-cell-like (ABC) DLBCL. Previous studies suggested that chronic B-cell receptor signaling and increased NF-κB activation contribute to ABC DLBCL survival. Here we show that the activity of the transcription factor NFAT is chronically elevated in both DLBCL subtypes. Surprisingly, NFAT activation is independent of B-cell receptor signaling, but mediated by an increased calcium flux and calcineurin-mediated dephosphorylation of NFAT. Intriguingly, although NFAT is activated in both DLBCL subtypes, long-term calcineurin inhibition with cyclosporin A or FK506, both clinically approved drugs, triggers potent cytotoxicity specifically in ABC DLBCL cells. The antitumor effects of calcineurin inhibitors are associated with the reduced expression of c-Jun, interleukin-6, and interleukin-10, which were identified as NFAT target genes that are particularly important for the survival of ABC DLBCL. Furthermore, calcineurin blockade synergized with BCL-2 and MCL-1 inhibitors in killing ABC DLBCL cells. Collectively, these findings identify constitutive NFAT signaling as a crucial functional driver of ABC DLBCL and highlight calcineurin inhibition as a novel strategy for the treatment of this aggressive lymphoma subtype.
650    _2
$a kalcineurin $x chemie $7 D019703
650    _2
$a inhibitory kalcineurinu $x farmakologie $7 D065095
650    _2
$a vápník $x metabolismus $7 D002118
650    _2
$a proliferace buněk $7 D049109
650    _2
$a lidé $7 D006801
650    _2
$a difúzní velkobuněčný B-lymfom $x farmakoterapie $x metabolismus $x patologie $7 D016403
650    _2
$a protein MCL-1 $x genetika $x metabolismus $7 D064549
650    _2
$a transkripční faktory NFATC $x antagonisté a inhibitory $x metabolismus $7 D050778
650    _2
$a protoonkogenní proteiny c-bcl-2 $x genetika $x metabolismus $7 D019253
650    _2
$a nádorové buňky kultivované $7 D014407
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Erdmann, Tabea $u Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany.
700    1_
$a Grondona, Paula $u Interfaculty Institute for Biochemistry, Eberhard Karls University, Tübingen, Germany.
700    1_
$a Xu, Wendan $u Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany.
700    1_
$a Schmitt, Anja $u Interfaculty Institute for Biochemistry, Eberhard Karls University, Tübingen, Germany.
700    1_
$a Schürch, Christoph $u Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.
700    1_
$a Zapukhlyak, Myroslav $u Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany.
700    1_
$a Schönfeld, Caroline $u Interfaculty Institute for Biochemistry, Eberhard Karls University, Tübingen, Germany.
700    1_
$a Serfling, Edgar $u Department of Molecular Pathology, University of Würzburg, Würzburg, Germany.
700    1_
$a Kramer, Daniela $u Interfaculty Institute for Biochemistry, Eberhard Karls University, Tübingen, Germany.
700    1_
$a Grau, Michael $u Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany.
700    1_
$a Klener, Pavel $u Institute of Pathological Physiology, First Faculty of Medicine, and. Department of Hematology, Charles University General Hospital Prague, Prague, Czech Republic.
700    1_
$a Lengerke, Claudia $u Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland. Division of Hematology, University Hospital Basel, Basel, Switzerland.
700    1_
$a Schulze-Osthoff, Klaus $u Interfaculty Institute for Biochemistry, Eberhard Karls University, Tübingen, Germany. German Cancer Consortium (DKTK), Heidelberg, Germany. German Cancer Research Center (DKFZ), Heidelberg, Germany; and. Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies," University of Tübingen, Tübingen, Germany.
700    1_
$a Lenz, Georg $u Department of Medicine A, Hematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany.
700    1_
$a Hailfinger, Stephan $u Interfaculty Institute for Biochemistry, Eberhard Karls University, Tübingen, Germany. Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies," University of Tübingen, Tübingen, Germany.
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 135, č. 2 (2020), s. 121-132
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31794606 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214125543 $b ABA008
999    __
$a ok $b bmc $g 1595556 $s 1113913
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 135 $c 2 $d 121-132 $e 20200109 $i 1528-0020 $m Blood $n Blood $x MED00000807
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace